IPF-025

Idiopathic Pulmonary Fibrosis (IPF)

Toronto 76 years old male Canada Total Cost: 234

Patient Condition

The patient presented with progressive dyspnea and weight loss and had a history of smoking (35 pack years). HRCT showed extensive cellular lung. Lung function: FVC 45% predicted, DLCO 28% predicted. 6MWD 230m, mMRC score 4. Compiled with type 2 diabetes and hypertension. Advanced IPF was diagnosed.

Treatment Timeline

PhaseDetailsDate
integrated assessment
treatment initiation
Treatment and monitoring (months 1-12)
Maintenance treatment (Months 13-24)

Treatment Outcome

beforeFVC accounted for 45% of predicted value, DLCO accounted for 28% of predicted value, 6MWD 230m, mMRC score 4, GAP score 6 (Phase III)
afterAfter 24 months of treatment, FVC accounted for 40% of the predicted value (annual decline rate was approximately 2.5%), DLCO accounted for 23% of the predicted value, 6MWD was 220m, and mMRC score was 4
highlightTreatment with Nintedanib can still effectively delay progression in elderly patients with advanced IPF, with an annual decline rate lower than natural disease. Palliative treatment improves quality of life.

Similar Cases

Related Recommendations